Glycopyrronium bromide

Phase 3

NOVARTIS AG (NVSEF)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Chronic Obstructive Pulmonary Disease

AZNTreatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate

Phase 3

View Full Landscape

Drug Information

Target Indication

Chronic Obstructive Pulmonary Disease

Clinical Trial

NCT00929110

Last updated: 3/17/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA9/15/2016

Sialanar

Symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders.

View on EMA

EMA9/28/2012

Tovanor Breezhaler

Tovanor Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

View on EMA

EMA9/28/2012

Seebri Breezhaler

Seebri Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

View on EMA

EMA9/28/2012

Enurev Breezhaler

Enurev Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

NVSEF

NOVARTIS AG

Biotechnology•North America•NASDAQ

Related Pipeline

dovitinibPhase 3

Solid Tumors

Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccinePhase 3

Swine-Origin Influenza A H1N1 Virus